Schedule an Appointment


Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Biopep Solutions Inc.

Location: Richmond, British Columbia

Sector: Life Science


Add to Shortlist
Express Interest

Biopep Solutions Inc. is a privately owned, late-preclinical stage biotechnology company whose general mission is to discover and develop innovative therapeutic products for the treatment of cancers and other diseases.

Business Documents

MG cp Summary

Need for a drug that is not susceptible to drug resistance  –The overwhelming majority of anticancer drugs on the market today are susceptible to resistance and become less effective or ineffective over time.


Need for a cancer therapy with minimal side effects –  Cancer therapies are known to be some of the more toxic therapies available. As well as being toxic, they are often non-specific meaning that they do not only target cancerous tissue, healthy tissue is also effected.


Need for effective late stage prostate cancer therapy –  If caught early, prostate cancer is often treatable. However late-stage prostate cancer patients have fewer effective treatment options.


Cancer is a very aggressive indication that finds alternative pathways to multiply.  Current therapies target singular pathways that.  Consequently a patient must enlist multiple therapies to conquer the aggressive nature of a cancer  Cancer’s multivalent mechanism is the processes by which cancer cells use more than one channel to grow and spread. BPS-001’s multivalent mechanism responds to this occurrence by targeting these channels.

Their lead drug candidate, BPS-001, is a unique disruptive therapy for various forms of cancer.  The initial target indication is prostate cancer.  Unlike conventional therapies like chemotherapy, hormone depravation therapy or immunotherapy, BPS-001 has the following advantages.

  • A multivalent mechanism, which targets multiple pathways and sites on the cancer cell, which means the cancer will be unable to develop resistance to the treatment which is the case in current
  • Inhibits angiogenesis (the formation of new blood vessels from existing blood vessels).
  • Increases apoptosis (a process of programmed cell death) of cancer cells.
  • Exhibits properties that counter inflammation.
  • BPS-001 has very low toxicity giving it a large therapeutic
  • Ease of administration, a once weekly subcutaneous

Ahmed Merzouk, Director, President and Chief Executive Officer

Dr. Merzouk has more than 20 years’ experience in industry and academia in drug discovery of small and large molecules. The expertise of Dr. Merzouk ranges from design, synthesis, and purification of synthetic molecules to extraction of active ingredients from natural sources.


Yalcin Ilsever, PhD, CPA.CGA, IMA(USA),FICBDirector, Executive Vice President and Chief Financial Officer

Dr. Ilsever is a Chartered Professional Accountant (CPA). His PhD is in  Accounting, Finance and Statistical Measurement. He has extensive experience in the private sector in the issuance of fixed income securities and equities. Dr. Ilsever has also published extensively on electronic commerce platforms, and business measurement systems.


Gary Yalloway, PhD, Director, Vice President, Regulatory Affairs and Drug Development

Dr. Yalloway has over 22 years of multidisciplinary experience in industry and academia and skills in enzyme engineering and protein purification of proteins of medical and industrial interest. He has significant experience in regulatory affairs with both the US Food and Drug Administration and Health Canada. He is highly experienced in all aspects of R&D, process development, and the scale-up and manufacture of therapeutic proteins. His specialties include upstream and downstream processing, including large-scale production and bulk manufacturing of recombinant proteins.